TiGenix has seen its Crohn’s disease candidate receive orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at Crohn’s disease – …

This awesome article FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉



Source link